

2008 Full Year Results

March 2009



Solutions with you in mind

Disclaimer

This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.


2008: A growth year for Almirall (I)

- Strong financial results.
- Yearly financial targets achieved.
- Performance in line with guidance and market consensus:

- Net Sales: €902,8 MM (+13,9%)

- Other Income: €153,1 MM (+22,6%)
- R&D: €139,3 MM (+14,1%)
- EBITDA: €230,0 MM (+35,0%)
- Net Income: €136,1 MM (+3,8%)
- EPS: €0,82 (+3,8%)

• 38,6% Dividend to be proposed to AGM in May.





2008: A growth year for Almirall (II)

- Solid evolution of current portfolio, higher weight of international sales.
- 2007 acquisitions fully integrated, synergies achieved.
- International expansion furthered (four new affiliates).
- Two important license-in agreements: *sitagliptin* (from MSD) and *amlodipine* + *atorvastatin* (from Pfizer).
- Pipeline with significant potential moving forward:
 - AB showed to improve lung function and was well tolerated in the Phase III trials with a desirable risk benefit profile. New clinical trials to start in 2009. US Filing timeline under review.
 - OD LABA moving forward, recent newsflow.
 - Two derma products filed in Q4 2008.



Almirall since IPO: Consistency with strategic goals

	2006	2007	2008
Defend leadership position in Spain:			
- Net sales	517,1	521,3	534,0
- Headcount ¹	791	799	814
 Market share² 	5,8%	5,6%	5.5%
International expansion:			
 Affiliates sales 	161,0	186,4	275,1
 License out / Corporate 	79,9	84,8	93,6
- % of total sales	31,8%	34,2%	40,8%
- # affiliates	6	6	10
Leverage own R&D:			
- R&D expense	86,6	122,0	139,3
- % of sales	11,5%	15,4%	15,4%
Notes:			
 Includes only the Spanish Commercial Area. IMS Audited Sales MAT Dec. 2006, 2007 and 2008. 			🖲 Almirall

2008 Financial Highlights

Key financial data

Net sales: € 902,8 MM (+13,9%)

Other Income: € 153,1 MM (+22,6%)

R&D: € 139,3 MM (+14,1%)

EBITDA: € 230,0 MM (+35,0%)

Net Income: € 136,1 MM (+3,8%)

Normalized Net Income: € 142,5 MM (+5,8%)

EPS: € 0,82 (+3,8%)

Net Debt: 0,73 x EBITDA

DPS: c. € 0,316

Equity / Total Assets: 46,8%

ROE: 26,3%



Total Revenue


€ 1,056 Bn

(+15, 1%)

Key investment ratios

EBITDA growth driven by Sales of new businesses, costs and OPEX containment and Other Income from partners offsetting increased R&D.

(€ Million)




Key Takeaways

- Strong growth in affiliates, steady growth in Spain, Sales up 13,9%
- Improved Gross Profit (1,9pp on sales).
- R&D increase reflects pipeline progression (+14%).
- SG&A increase linked to new affiliates and new businesses.
- Other Income improvement linked to contributions to development and milestones from partners (+23%).
- Depreciation increase due to 2007 acquisitions.



Strong growth in affiliates, steady growth in Spain (€ Million)




Key Takeaways

- Strong growth in affiliates (+47,6%) driven by Germany, United Kingdom and new businesses, steady growth in Spain (+2,4%)
- Price erosion in Spain below 1% (application of the 2007 Medicines Law).
- Very limited effect (less than 1% of sales) of exchange rate.



Other Income increase linked to contributions to development and milestones from partners

(€ Million)



Other Income

€Million	2008	2007	% variation
Revenues under co-promotion agreements (1)	31,7	28,0	13,1%
Collaboration in product promotion	28,6	28,7	-0,1%
Revenues under co-development agreements/Other	81,4	58,1	40,3%
Revenue from the sale/transfer of product marketing rights	2,5	1,1	130,5%
Royalties	2,1	1,5	38,2%
Subsidies	3,4	1,5	131,3%
Other Income	3,5	6,1	-43,1%
Total	153,1	124,9	22,6%

⁽¹⁾ Includes accruals of amounts from Sanofi- Aventis relating to Actonel, Fumaderm and Reckitt Benckiser margin

Key Takeaways

- Contributions to development have increased significantly due mainly to AB Phase III (ACCLAIM studies).
- Various payments linked to AB milestones and almotriptan in the US.



Positive Gross Margin and Expenses Evolution (€ Million)

Gross Profit Evolution (Absolute and % over sales) Headlines and key drivers Gross Profit: Significant improvement (1.9pp on 61,2% 63,1% sales) +17,5% significan improvement Miscellaneous costs savings (including import of some raw materials from Asia). Due to a favourable product mix (new affiliates 484.6 569,4 and new products). 2007 2008 SG&A Expenses Evolution (Absolute and % over sales) +19,1% D&A SG&A: Increase of 12% (below sales growth) if 44,3% 46,3% D&A are excluded. New affiliates created in 2008. • Increase of D&A due to 2007 acquisitions. • 351,2 418,2 2007 2008 **R&D Expenses Evolution** (Absolute and % over sales) **R&D:** Increase reflects pipeline progression. 15,4% 15,4% + 14,1% Variation in absolute values Phase III of aclidinium bromide monotherapy. Rest of pipeline moving forward, including the derma pipeline. 122 139,3 2007 2008 10

Income Statement

Net Sales 902,8 792,5 13,9% steady growth in Spain. Gross Profit 569,4 484,6 17,5% steady growth in Spain. % of sales 63,1% 61,2% Significant improvement due to favourable production mix and miscellaneo cost savings. % of sales -15,4% -15,4% 14,1% mix and miscellaneo cost savings. % of sales -46,3% -44,3% 19,1% 12%	€Million	2008	2007	% variation		Strong growth in affiliates,
% of sales $63,1\%$ $61,2\%$ Other Income $153,1$ $124,9$ $22,6\%$ R&D $-139,3$ $-122,0$ $14,1\%$ % of sales $-15,4\%$ $-15,4\%$ SG&A $-418,2$ $-351,2$ $19,1\%$ % of sales $-46,3\%$ $-44,3\%$ Other Op. Exp $1,6$ $-2,0$ $n.m$ % of sales $0,2\%$ $-0,3\%$ $I2\%$ BIT $166,7$ $134,3$ $24,1\%$ % of sales $0,2\%$ $-0,3\%$ $I6,9\%$ Depreciation $63,3$ $36,0$ $75,7\%$ % of sales $7,0\%$ $4,5\%$ $I6,9\%$ BITDA $230,0$ $170,3$ $35,0\%$ Sale of noncurrent assets / Other $0,8$ $0,0$ $n.m$ Net income $136,1$ $131,2$ 3.8% Norm alized Net Income $136,1$ $131,2$ 3.8% Normalized Earnings per share (€) $0,86 \in$ $0,81 \in$ EPS improvement of 3,6	Net Sales	902,8	792,5	13,9%	K	
Other Income153,1124,922,6%R&D-139,3-122,014,1%% of sales $-15,4\%$ $-15,4\%$ $-15,4\%$ SG&A $-418,2$ $-351,2$ 19,1%12%% of sales $-46,3\%$ $-44,3\%$ 0 Other Op. Exp $1,6$ $-2,0$ n.m% of sales $0,2\%$ $-0,3\%$ 0 EBIT166,7134,324,1%% of sales $18,5\%$ 16,9%Depreciation $63,3$ $36,0$ % of sales $7,0\%$ $4,5\%$ Sale of noncurrent assets / Other $0,8$ $0,0$ Reestructuring costs $0,0$ $0,0$ $n.m$ Net financial income / (expenses) $-17,7$ $5,0$ $n.m$ Norm alized Net Income $142,5$ $134,6$ 5.8% Earnings per share (\in) ($^{(1)}$ $0,82 \in$ $0,79 \in$ Normalized Earnings per share (\in) $0,86 \in$ $0,81 \in$	Gross Profit	569,4	484,6	17,5%	\leq	
Other Income153,1124,922,6%R&D-139,3-122,014,1%% of sales-15,4%-15,4%SG&A-418,2-351,219,1%Yo of sales-46,3%-44,3%Other Op. Exp1,6-2,0n.m% of sales0,2%-0,3%EBIT166,7134,324,1%% of sales18,5%16,9%Depreciation63,336,075,7%% of sales7,0%4,5%EBITDA230,0170,335,0%Sale of noncurrent assets / Other0,80,0n.mReestructuring costs0,00,0n.mImpairment losses-5,1-10,2n.mNet income136,1131,23,8%Norm alized Net Income142,5134,65,8%Earnings per share (€)0,86 €0,81 €	% of sales	63,1%	61,2%			Significant improvement
R&D-139,3-122,014,1%mix and miscellaneo cost savings.% of sales-15,4%-15,4%mix and miscellaneo cost savings.% of sales-418,2-351,219,1%12%% of sales-46,3%-44,3%Ø of sales0,2%-0,3%BIT166,7134,324,1%% of sales18,5%16,9%Depreciation63,336,075,7%% of sales7,0%4,5%EBITDA230,0170,335,0%% of sales25,5%21,5%Sale of noncurrent assets / Other0,80,0n.mImpairment losses-5,1-10,2n.mNet financial income / (expenses)-17,75,0n.mTax-8,62,1n.mNet income136,1131,23.8%Normalized Net Income142,5134,65.8%Earnings per share (€) (1)0,82 €0,79 €Normalized Earnings per share (€)0,86 €0,81 €	Other Income	153,1	124,9	22,6%		
% of sales -15,4% -15,4% SG&A -418,2 -351,2 19,1% 12% % of sales -46,3% -44,3% Other Op. Exp 1,6 -2,0 n.m % of sales 0,2% -0,3% EBIT 166,7 134,3 24,1% % of sales 18,5% 16,9% Depreciation 63,3 36,0 75,7% % of sales 7,0% 4,5% EBITDA 230,0 170,3 35,0% % of sales 2,55% 21,5% Sale of noncurrent assets / Other 0,8 0,0 n.m Reestructuring costs 0,0 0,0 n.m Impairment losses -5,1 -10,2 n.m Net financial income / (expenses) -17,7 5,0 n.m Tax -8,6 2,1 n.m Net income 136,1 131,2 3.8% Normalized Net Income 142,5 , 134,6 5.8% Earnings per share (€) (1) 0,82 € 0,79 € Normalized Earnings per share (€) 0,86 € 0,81 €	R&D	-139,3	-122,0	14,1%		
SG&A-418,2-351,219,1%12%% of sales-46,3%-44,3%Other Op. Exp1,6-2,0n.m% of sales0,2%-0,3%EBIT166,7134,324,1%% of sales18,5%16,9%Depreciation63,336,075,7%% of sales7,0%4,5%EBITDA230,0170,335,0%% of sales25,5%21,5%Sale of noncurrent assets / Other0,80,0mpairment losses-5,1-10,2n.mNet financial income / (expenses)-17,75,0n.mTax-8,62,1n.mNet income136,1131,23.8%Normalized Net Income142,5134,65.8%Earnings per share (€) (¹)0,82 €0,79 €Normalized Earnings per share (€)0,86 €0,81 €	% of sales	-15,4%	-15,4%			
Other Op. Exp1,6-2,0n.m% of sales $0,2\%$ $-0,3\%$ EBIT166,7134,324,1%% of sales $18,5\%$ $16,9\%$ Depreciation63,336,075,7%% of sales $7,0\%$ $4,5\%$ EBIT DA230,0170,335,0%% of sales $25,5\%$ $21,5\%$ Sale of noncurrent assets / Other $0,8$ $0,0$ $n.m$ Meestructuring costs $0,0$ $0,0$ $n.m$ Impairment losses $-5,1$ $-10,2$ $n.m$ Net financial income / (expenses) $-17,7$ $5,0$ $n.m$ Tax $-8,6$ $2,1$ $n.m$ Net income136,1131,2 3.8% Normalized Net Income $142,5$ $134,6$ 5.8% Earnings per share (\in) (1) $0,82 \in 0,79 \in$ $0,81 \in$ Normalized Earnings per share (\in) $0,86 \in 0,81 \in$ $0,81 \in$	SG&A	-418,2	-351,2	19,1%	12%	
% of sales $0,2\%$ -0,3% EBIT 166,7 134,3 24,1% % of sales 18,5% 16,9% Depreciation 63,3 36,0 75,7% % of sales 7,0% 4,5% EBITDA 230,0 170,3 35,0% % of sales 25,5% 21,5% Sale of noncurrent assets / Other 0,8 0,0 n.m Reestructuring costs 0,0 0,0 n.m Impairment losses -5,1 -10,2 n.m Net financial income / (expenses) -17,7 5,0 n.m Tax -8,6 2,1 n.m Net income 136,1 131,2 3.8% Normalized Net Income 142,5 , 134,6 5.8% Earnings per share (€) ⁽¹⁾ 0,82 € 0,79 € Normalized Earnings per share (€) 0,86 € 0,81 €	% of sales	-46,3%	-44,3%			
% of sales $0,2\%$ $-0,3\%$ (below Sales growth)EBIT166,7134,324,1%% of sales18,5%16,9%Depreciation63,336,075,7%% of sales7,0%4,5%Very significant improvement of EBITDAVery significant improvement of EBITDA% of sales25,5%21,5%Sale of noncurrent assets / Other0,80,0n.mMet financial income / (expenses) $-17,7$ 5,0n.mPercent of the salesDepreciationNet income136,1131,23.8%EPS improvement of 3,8Normalized Net Income142,5 $, 134,6$ 5.8% EPS improvement of 3,8Normalized Earnings per share (€) $0,86 \in$ $0,81 \in$ EPS improvement of 3,8	Other Op. Exp	1,6	-2,0	n.m		SG&A increase of 12%
EBIT166,7134,324,1%D&A are excluded.% of sales18,5%16,9% $16,9\%$ $0,9\%$ $0,9\%$ $0,9\%$ Depreciation63,336,075,7% $7,0\%$ $4,5\%$ Very significant improvement of EBITDA% of sales7,0%4,5% $25,5\%$ 21,5% $35,0\%$ $170,3$ $35,0\%$ Sale of noncurrent assets / Other0,80,0n.m $mprovement$ of EBITDA $driven$ by sales of new businesses, cost and $OPEX$ containment and $OHer Income$ from partners. $OPEX$ containment and $Other Income frompartners.Net financial income / (expenses)-17,75,0n.m0,0PEX containment andOther Income frompartners.Net income136,1131,23.8%0,79 \inEPS improvement of 3,8Normalized Net Income0,82 \in 0,79 \in0,81 \inPS improvement of 3,8$	% of sales	0,2%	-0,3%			
Depreciation63,336,075,7%% of sales7,0%4,5%EBITDA230,0170,335,0%% of sales25,5%21,5%Sale of noncurrent assets / Other0,80,0n.mReestructuring costs0,00,0n.mImpairment losses-5,1-10,2n.mNet financial income / (expenses)-17,75,0n.mTax-8,62,1n.mNet income136,1131,23.8%Earnings per share (€) ⁽¹⁾ 0,82 €0,79 €Normalized Earnings per share (€)0,86 €0,81 €	EBIT	166,7	134,3	24,1%		
% of sales7.0%4,5%EBITDA230,0170,335,0%% of sales25,5%21,5%Sale of noncurrent assets / Other0,80,0n.mReestructuring costs0,00,0n.mImpairment losses-5,1-10,2n.mNet financial income / (expenses)-17,75,0n.mTax-8,62,1n.mNet income136,1131,23.8%Normalized Net Income142.5134,65.8%Earnings per share (€) ⁽¹⁾ 0,82 €0,79 €Normalized Earnings per share (€)0,86 €0,81 €	% of sales	18,5%	16,9%			
EBITDA230,0170,335,0%Very significant improvement of EBITDA driven by sales of new businesses, cost and OPEX containment and OPEX containment and Other Income from partners.% of sales $25,5\%$ $21,5\%$ $n.m$ Sale of noncurrent assets / Other $0,8$ $0,0$ $n.m$ Reestructuring costs $0,0$ $0,0$ $n.m$ Impairment losses $-5,1$ $-10,2$ $n.m$ Net financial income / (expenses) $-17,7$ $5,0$ $n.m$ Tax $-8,6$ $2,1$ $n.m$ Net income136,1 $131,2$ 3.8% Normalized Net Income 142.5 $134,6$ 5.8% Earnings per share (€) (1) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (€) $0,86 \in$ $0,81 \in$	Depreciation	63,3	36,0	75,7%		
LBIT DA230,0170,333,0%improvement of EBITDA% of sales $25,5\%$ $21,5\%$ improvement of EBITDASale of noncurrent assets / Other $0,8$ $0,0$ $n.m$ Reestructuring costs $0,0$ $0,0$ $n.m$ Impairment losses $-5,1$ $-10,2$ $n.m$ Net financial income / (expenses) $-17,7$ $5,0$ $n.m$ Tax $-8,6$ $2,1$ $n.m$ Net income136,1131,2 3.8% Normalized Net Income $142,5$ $134,6$ 5.8% Earnings per share (\in) (1) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (\in) $0,86 \in$ $0,81 \in$	% of sales	7,0%	4,5%			Verne eiereifie ent
% of sales $(25,5\%)$ $(21,5\%)$ $(21,5\%)$ $(21,5\%)$ $(11,5\%)$ <td>EBITDA</td> <td>230,0</td> <td>170,3</td> <td>35,0%</td> <td>\leftarrow</td> <td></td>	EBITDA	230,0	170,3	35,0%	\leftarrow	
Sale of noncurrent assets / Other $0,8$ $0,0$ $n.m$ Reestructuring costs $0,0$ $0,0$ $n.m$ Impairment losses $-5,1$ $-10,2$ $n.m$ Net financial income / (expenses) $-17,7$ $5,0$ $n.m$ Tax $-8,6$ $2,1$ $n.m$ Net income 136,1131,23.8% Normalized Net Income 142,5 $134,6$ 5.8% Earnings per share (\in) (1) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (\in) $0,86 \in$ $0,81 \in$	% of sales	25,5%	21,5%		•	
Reestructuring costs $0,0$ $0,0$ $n.m$ Impairment losses $-5,1$ $-10,2$ $n.m$ Net financial income / (expenses) $-17,7$ $5,0$ $n.m$ Tax $-8,6$ $2,1$ $n.m$ Net income 136,1131,23.8% Normalized Net Income 142,5 $134,6$ 5.8% Earnings per share (\in) (1) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (\in) $0,86 \in$ $0,81 \in$	Sale of noncurrent assets / Other	0,8	0,0	n.m		
Impairment losses $-5,1$ $-10,2$ n.mNet financial income / (expenses) $-17,7$ $5,0$ n.mTax $-8,6$ $2,1$ n.mNet income 136,1131,23.8% Normalized Net Income 142,5134,65.8% Earnings per share (€) (1) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (€) $0,86 \in$ $0,81 \in$	Reestructuring costs	0,0	0,0	n.m		· · · · · · · · · · · · · · · · · · ·
Net financial income / (expenses) $-17,7$ $5,0$ n.mTax $-8,6$ $2,1$ n.mNet income136,1 $131,2$ 3.8% Normalized Net Income 142.5 $134,6$ 5.8% Earnings per share (€) (1) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (€) $0,86 \in$ $0,81 \in$	Impairment losses	-5,1	-10,2	n.m		
Tax $-8,6$ $2,1$ n.m Net income 136,1 131,2 3.8% Normalized Net Income 142,5 134,6 5.8% Earnings per share (€) ⁽¹⁾ $0,82 \in$ $0,79 \in$ EPS improvement of 3,8 Normalized Earnings per share (€) $0,86 \in$ $0,81 \in$ EPS improvement of 3,8	Net financial income / (expenses)	-17,7	5,0	n.m		
Normalized Net Income142.5134.65.8%Earnings per share (\in) (1)0,82 \in 0,79 \in Normalized Earnings per share (\in)0,86 \in 0,81 \in	Тах	-8,6	2,1	n.m		
Earnings per share (\in) (1) $0,82 \in 0,79 \in$ EPS improvement of 3,8 Normalized Earnings per share (\in) $0,86 \in 0,81 \in$	Netincome	136,1	131,2	3.8%		
Earnings per share (\in) $0,82 \in$ $0,79 \in$ Normalized Earnings per share (\in) $0,86 \in$ $0,81 \in$	Normalized Net Income	142.5	134,6	5.8%		EPS improvement of 2.9%
	Earnings per share (€) ⁽¹⁾	0,82€	0,79€			
Nu. of employees end of period 3.344 3.357 -0,4%	Normalized Earnings per share (€)	0,86€	0,81€			
	Nu. of employees end of period	3.344	3.357	-0,4%		

⁽¹⁾ Number of shares at the end of the period



Almirall: Solid underlying P&L

Positive evolution of strong fundamentals

€MM	2006	2007	2008
Net Sales	758,0	792,5	902,8
Gross Margin	62,6%	61,2%	63,1%
R&D	11,4%	15,4%	15,4%
SG&A (w/o depreciation)	46,9%	42,2%	41,6%
EBITDA	19,0%	21,5%	25,5%



Solid balance sheet with further leverage potential

Balance Sheet

€Million	2008	% of BS	2007	Increase in depreciation
Goodw ill	273,5	19,6%	274,3	due to new businesses (€ 29 MM).
Intangible assets	342,7	24,5%	383,4	
Property, plant and equipment	175,7	12,6%	179,3	Key Takeaways
Financial assets	3,9	0,3%	6,3	
Other non current assets	165,3	11,8%	144,2	NET DEBT :
Total Non Current Assets	961,1	68,8%	987,5	Financial debt (€321 MM) - Cash & Equivalents (€186,1 MM) + Pensions &
Inventories	112,5	8,1%	112,8	Equivalents (€ 100,1 mm) + Pensions & Funds (€ 32,9 MM) =
Accounts receivables	107,9	7,7%	107,0	€167,8 MM
Cash & equivalents	186,1	13,3%	190,0	
Other current assets	28,8	2,1%	41,8	x 0,73 EBITDA 2008
Total Current Assets	435,3	31,2%	451,6	
Total Assets	1.396,4		1.439,1	
				+ 2008 Income (€136 MM)
Shareholders equity	653,0	46,8%	573,7	- Dividend payment (€52,5MM)
Financial debt	321,0	< 23,0%	466,2	
Other non current liabilities	183,3	13,1%	187,4	Financial debt reduction
Other current liabilities	239,1	17,1%	211,8	amounting €145 MM
Total Equity and Liabilities	1.396,4		1.439,1	




Strong cash flow generation

€ 233,1 MM Cash Flow generation from Operating Activities in 2008

Cash Flow Figures

€Million	2008	2007		Impact of 2007
Profit Before Tax	144,7	129,2	L	acquisitions.
Depreciation and amortisation	63,3	36,0		Improvement of working
Change in w orking capital	16,2	-26,8	l	capital vs. last year.
Other adjustments	8,9	40,6		
Cash Flow from Operating Activities	233,1	179,0		
Financial Income	6,8	21,3		Tight CAPEX management.
Investments	-24,0	-582,3	_	
Divestments	2,9	108,9		
Changes in scope of consolidation	0,0	-85,9		Hermal acquisition.
Other cash flow s	0,0	6,7	//	Sales of Financial Assets.
Cash Flow from Investing Activities	-14,3	-531,2		
Finance Expense	-25,1	-14,4		Includes Hermal tangible
Dividends distribution	-52,5	-420,0		& intangible assets incorporation.
Capital increase/ (decrease)	0,0	106,7		
Debt increase/ (decrease)	-145,2	460,4		
Other cash flow s	0,1	-12,0		
Cash Flow from Financing Activities	-222,7	120,7		Debt cancellation.
Cash Flow generated during the period	-3,9	-231,5		
Free Cash Flow	218,8	-352,2		
				🖲 Almirall

Strong and steady Cash Flow generation





2008 Operations Highlights

- Sales increase (+13,9%) led by International Sales (+36%).
- International Sales driven by UK and Germany.
- Solid performance of Top-10 products (+2,1%), driven by Esertia, Parapres, Prevencor and Opiren.
- 2007 acquisitions fully integrated, rolling out of derma portfolio.
- Two significant license-in agreements in Spain:
 - Tesavel[®] (*sitagliptin*) from MSD.
 - Astucor[®] (*amlodipine* + *atorvastatin*) from Pfizer.
- Four new affiliates (UK, Austria, Switzerland and Poland).
- Efficiency gains and asset optimization achieved:
 - Sinergies from 2007 acquisitions
 - Early 2009: divestment of 13 products



New Licensed Products in 2008

Tesavel[®] (*sitagliptin*)

- New type 2 diabetes medicine that addresses glycemic control.
- Co-marketing agreement with Merck Sharp & Dohme (MSD) which grants Almirall marketing rights for *sitagliptin* in Spain.
- Product launched in December 2008.
- In 2009, launch of a new sitagliptin and metformin combination product in a single tablet and which Almirall will also be marketing under the name Efficib[®].

Astucor[®] (*amlodipine* + *atorvastatin*)

- New medicine that reduces the risk of non-fatal myocardium infarction and fatal coronary disease by 53% in high cardiovascular risk hypertense patients.
- Co-marketing agreement with Pfizer which grants Almirall commercialisation rights in Spain.
- Product launched in January 2009.



Sales by Region and Business

Net Sales breakdown by Geographic Area				Net Sales breakdown by Distribution Channel				
2008	2007	% Variation	€Million	2008	2007	% Variation		
534,0	521,3	2,4%	Own sales Network (within Spain)	534,0	521,3	2,4%		
269,0	178,6	50,6%	Own sales Network					
66,6	73,8	-9,8%	(other countries)	275,1	186,4	47,6%		
33,1	18,7	77,6%	Marketing with licensees	60,5	66,1	-8,4%		
			Corporate	33,1	18,7	77,6%		
902,8	792,5	13,9%	Total	902,8	792,5	13,9%		
	2008 534,0 269,0 66,6 33,1	2008 2007 534,0 521,3 269,0 178,6 66,6 73,8 33,1 18,7	2008 2007 % Variation 534,0 521,3 2,4% 269,0 178,6 50,6% 66,6 73,8 -9,8% 33,1 18,7 77,6%	2008 2007 % Variation € Million 534,0 521,3 2,4% Own sales Network (within Spain) 269,0 178,6 50,6% Own sales Network (other countries) 66,6 73,8 -9,8% Own sales Network (other countries) 33,1 18,7 77,6% Marketing with licensees 902.8 792.5 13.9% Own sales Network	2008 2007 % Variation € Million 2008 534,0 521,3 2,4% Own sales Network (within Spain) 534,0 269,0 178,6 50,6% Own sales Network (within Spain) 534,0 66,6 73,8 -9,8% Own sales Network (other countries) 275,1 33,1 18,7 77,6% Marketing with licensees 60,5 902.8 792.5 13.9% 13.9% 13.9%	2008 2007 % Variation € Million 2008 2007 534,0 521,3 2,4% Own sales Network (within Spain) 534,0 521,3 269,0 178,6 50,6% Own sales Network (within Spain) 534,0 521,3 66,6 73,8 -9,8% Own sales Network (other countries) 275,1 186,4 33,1 18,7 77,6% Marketing with licensees 60,5 66,1 902.8 792.5 13.9% 60.5 66,1 73,9		

Key takeaways

- Significant increase of International in the overall sales.
- International growth led by Germany and United Kingdom.
- Corporate Sales improvement linked to toll manufacturing.



Top 10 Products Sales

Net Sales by PRODUCT

€Million	2008	2007	% Variation	% of Sales
Prevencor (atorvastatin)	104,8	92,8	12,9%	11,6%
Ebastine	100,7	100,4	0,2%	11,1%
Plusvent (salmeterol & fluticasone)	59,7	63,0	-5,3%	6,6%
Esertia (<i>escitalopram</i>) €561	55,6	47,3	17,4%	6,1%
Aceclofenac	2 50,0	52,7	€549M -5,2%	5,5%
Dobupal (venlafaxine) + 2,1	46,8	51,1	-8,4%	5,2%
Almotriptan	44,0	47,4	-7,2%	4,9%
Parapres (candesartan cilexetile)	40,2	35,5	13,3%	4,4%
Opiren (lansoprazole)	35,2	32,6	7,9%	3,9%
Almax (almagate)	24,1	25,9	-6,8%	2,7%
Other	341,8	243,7	40,3%	37,8%
Total	902,8	792,5	13,9%	100%

Key takeaways

• +2,1% growth in top ten products, led by Esertia, Parapres, Prevencor and Opiren.

• Well-diversified portfolio: limited exposure to one single product.



Sales by Therapeutic Area

Net Sales by Therapeutic Area

€Million	2008	2007	% Variation	% of Sales
Cardiovascular	176,4	162,0	8,9%	19,5%
CNS	172,7	172,6	0,1%	19,1%
Respiratory	171,8	176,2	-2,5%	19,0%
Digestive	139,7	128,4	8,8%	15,5%
Dermatology	102,8	29,3	250,9%	11,4%
Osteomuscular	82,1	78,3	4,8%	9,1%
Urological	22,4	22,0	1,7%	2,5%
Other	34,9	23,6	44,1%	3,8%
Total	902,8	792,5	13,9%	100%

Key takeaways

- Dermatology sales raised by the incorporation of new portfolios.
- Lower respiratory driven by less asthma seasonality (*salmeterol+fluticasone*).
- Stable composition of sales in the rest of therapeutic areas.



Factors that will contribute to sustain the base business until 2011-12


- Solid, branded, patented and well balanced product portfolio.
- Current portfolio single digit top line sales evolution expected for 2009 and 2010 (excluding new Corporate Development projects).
- Increased dermatology area presence in the company portfolio enhances stability of sales evolution.
- Limited exposure to price/volume erosion in Spain until 2011/12.
- The Spanish market maintains a steady while slow to generic penetration.
- Roll out of derma portfolio and pipeline.
- ✓ Sativex opportunity.



Trends in the Spanish pharma market

Generic market evolution

Market trends





🖉 Almirall

Source: IMS audited sales MAT Dec 2005, 2006, 2007 and 2008

R&D Update (I)

Aclidinium bromide Monotherapy

- AB showed to improve lung function and was well tolerated in the Phase III trials with a desirable risk benefit profile.
- Meeting with FDA held in March.
- Regulatory interactions ongoing in EU.
- New clinical programme ready to go following regulatory authorities interactions.
 - Several studies to start in Q2 and Q3'09.
 - -To include head-to-head comparison with tiotropium (short term study).
- Publications/presentations at ATS (May 2009) and ERS (September 2009).



R&D Update (II)

Aclidinium bromide + Formoterol

- Phase IIb programme ongoing:
 - Results to date confirm additive effects.
 - Further studies to start immediately.

Aclidinium bromide + ICS

• Further definition of this programme following regulatory authorities interactions about mono programme.

R&D Update (III)

OD LABA

- LAS100977 progressing very well:
 - Two phase IIa studies in asthma completed with excellent results:
 - Multiple dose results confirm efficacy and safety profile seen in single dose study.
 - One study ongoing, results March / April.
 - Aim to present data at ATS 2010.
 - First trial with Genuair[®] device planned for 2Q-3Q'09.
 - Partnering discussions ongoing.
- LAS186368
 - Preclinical studies completed.
 - Programme on hold due to excellent progress on LAS100977.



R&D Update (IV)

Rest of Pipeline

- LAS186323 (DHODH inhibitor for RA / MS) progressing well:
 - Single dose FIM completed with torelability.
 - Backup (LAS187247) in pre-clinical development.
 - Licensing options under evaluation.
- Dermatology:
 - LAS41001, retinoid for *rosacea* filed.
 - One formulation of LAS41002 filed, a second to be filed in March'09.
 - A third formulation of LAS41002 in phase II, filing expected in 2010.
 - LAS41005, filing expected for Q4 2009.




A pipeline with significant upside

Auto-immune Respiratory

Dermatology

Pipeline Status (the right end of each bar represents status of development as of March 6th)







Solutions thinking of you

Targets and Guidance 2009

R&D Outlook 2009

Expected newsflow

Aclidinium bromide

- March/April'09 Market update after regulatory interactions (US and Europe).
- May'09 ATS Further details on *aclidinium bromide's* Phase III data.
- Sep.'09 ERS Further details on *aclidinium bromide's* Phase III data.
- During 2009, start of several *aclidinium bromide* clinical trials will be announced (including a head-to-head comparison with *tiotropium*).

Rest of Pipeline

- March'09 Sativex Phase III available (Spasticity).
- March/April'09 New data from one trial of LAS100977 (OD LABA).
- 2009 Filing of LAS41005, a combination for non-melanoma skin cancer.



Financial Outlook 2009

Financial guidance

- 2009 P&L perspectives :
 - Expected single digit growth in sales, EBITDA and Normalised Net Income.
 - Pay-out policy to be maintained at 35-40% (unless capital discipline and/or business requirements dictate otherwise).



Corporate Development Outlook 2009

Priorities for 2009

- Partnering AB in key geographies.
- Partnering of OD LABA (LAS100977).
- Pursuing new license-in opportunities.
- Continue to evaluate selected acquisitions.

Almirall – Sources of value creation and strategic goals

Strategic position

- R&D driven, focus on innovation.
- #1 Spanish pharma, #1 dermatology pharma in Germany and #7 across Europe.
- Diversified product portfolio with low exposure to price/volume erosion in Spain until 2011/12.

Drivers for growth


- Broadest and deepest pipeline in company history.
- Derma pipeline and portfolio roll out.
- Explore leveraging value from Genuair[®]

Capabilities / Opportunities

- R&D capabilities in Respiratory, Autoinmune and Dermatology.
- Presence in major Europe.
- Strong cash flow generation and solid balance sheet.









Solutions thinking of you

Almirall as investment case

Solid fundamentals focused on long term value creation

Combining a well-established businesswith significant upside from pipeline

- Branded, patented balanced portfolio.
- Spanish leadership.
- Strong cash-flow generation and solid balance sheet.


- Broadest and deepest pipeline in company history.
- Aclidinium bromide (AB) franchise promising OD LABA
- Explore leveraging value from Genuair[®] inhaler.

...complemented with proven Corporate Development activity

Proven record in Corporate Development : Sofotec acquisition (2006), AB partnering with Forest (2006), Hermal and Shire portfolio acquisitions (2007), *sitagliptin* and *amlodipine+atorvastatin* licences-in (2008).




Almirall – Focus on growth and value creation



Almirall's business model

A successful combination of R&D and corporate development







A stable, branded and well-balanced product portfolio


- ✓ Diversified risk across therapies, geographies, product sales and sources of portfolio.
- Limited exposure to price / volume erosion in Spain until 2011/2012.
- ✓ Strong partnerships.

	€Million	2008	%	Spain	Interna- tional
•	Prevencor (atorvastatine)	104,8	12	\checkmark	
•	Ebastine	100,7	11	\checkmark	\checkmark
•	Plusvent (salmeterol & fluticasone)	59,7	7	\checkmark	
•	Esertia (escitalopram)	55,6	6	\checkmark	
•	Aceclofenac	50,0	5	\checkmark	\checkmark
•	Dobupal (<i>venlafaxine</i>)	46,8	5	\checkmark	
•	Almotriptan	44,0	5	\checkmark	\checkmark
•	Parapres (candesartan cilexetile)	40,2	4	\checkmark	
•	Opiren (lansoprazole)	35,2	4	\checkmark	
•	Almax (almagate)	24,1	3	\checkmark	\checkmark
•••	Other	341,8	38	\checkmark	\checkmark
	Total	902,8	100		





Strong track record in pursuing opportunities



Moving Forward

- Roll out of Derma pipeline and portfolio.
- Sativex opportunity (Spasticity and Cancer pain).
- Aclidinium bromide partnering for Europe and Japan.
- Partnering for OD LABA.
- Pursuing new Corporate Development opportunities.
- Explore leveraging value from Genuair[®].



Genuair®: superior inhalation device

Designed for compliance with global regulatory standards (FDA, EMEA, Japan)

What makes our inhaler different?

✓ A preloaded device.

- ✓ A novel inhalation system which consists of only 2 steps: press and inhale.
- ✓ A unique device with three feedback to the patient: a control window which changes colour, taste following inhalation, and an audible signal indicating that inhalation has been completed correctly.
- ✓ User friendly, easy-to-use and safe for the patient.



Proven R&D track record and competitive capabilities

A focused strategy that balances risk and reward

International R&D capabilities with proven track record

- R&D expense above 15% of sales.
- 3 R&D centers in Spain and Germany with c. 600 staff.
- 40 years of R&D expertise, 7 international products launched successfully (first Spanish pharma company to get approvals in US, UK and Japan).




Sant Feliu R&D Centre (Barcelona)

Focused R&D strategy that balances risk and reward

- Key targeted areas : Respiratory (Asthma and COPD), Autoimmune (RA, MS, Psoriasis) and Dermatology.
- Priority to validated targets with high commercial value, core competence in drug discovery
- Licence out strategy after PoC (*Prove of Concept*) contributes to R&D financing.



Our history





For further information, please contact: Jordi Molina, Head of Investor Relations Ph. +34 93 291 3087 jordi.molina@almirall.com

Or visit our website: www.almirall.com





Solutions thinking of you